See more : Carpinienne de Participations (CARP.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Assertio Holdings, Inc. (ASRT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Assertio Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Formuepleje LimiTTellus (FPILIM.CO) Income Statement Analysis – Financial Results
- Inform P. Lykos Holdings S.A. (LYK.AT) Income Statement Analysis – Financial Results
- Brinker International, Inc. (EAT) Income Statement Analysis – Financial Results
- CT Real Estate Investment Trust (CRT-UN.TO) Income Statement Analysis – Financial Results
- Osino Resources Corp. (OSI.V) Income Statement Analysis – Financial Results
Assertio Holdings, Inc. (ASRT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.assertiotx.com
About Assertio Holdings, Inc.
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 152.07M | 156.23M | 111.01M | 106.28M | 229.50M | 311.77M | 380.72M | 455.90M | 342.74M | 390.36M | 134.21M | 90.82M | 132.97M | 80.76M | 57.73M | 34.84M | 65.58M | 9.55M | 4.41M | 202.57K | 981.99K | 1.66M | 3.67M | 1.78M | 115.33K | 800.00K | 600.00K | 300.00K |
| Cost of Revenue | 27.02M | 18.75M | 15.83M | 19.87M | 9.51M | 18.48M | 72.60M | 87.41M | 67.90M | 15.15M | 7.09M | 6.04M | 5.54M | 8.10M | 5.26M | 5.77M | 2.60M | 1.60M | 908.52K | 0.00 | 0.00 | 0.00 | 0.00 | -561.76K | -643.49K | -500.00K | -200.00K | 0.00 |
| Gross Profit | 125.05M | 137.49M | 95.18M | 86.40M | 220.00M | 293.29M | 308.13M | 368.48M | 274.84M | 375.22M | 127.11M | 84.78M | 127.43M | 72.67M | 52.47M | 29.07M | 62.99M | 7.95M | 3.50M | 202.57K | 981.99K | 1.66M | 3.67M | 2.34M | 758.82K | 1.30M | 800.00K | 300.00K |
| Gross Profit Ratio | 82.23% | 88.00% | 85.74% | 81.30% | 95.86% | 94.07% | 80.93% | 80.83% | 80.19% | 96.12% | 94.72% | 93.35% | 95.83% | 89.97% | 90.89% | 83.43% | 96.04% | 83.24% | 79.38% | 100.00% | 100.00% | 100.00% | 100.00% | 131.63% | 657.97% | 162.50% | 133.33% | 100.00% |
| Research & Development | 2.84M | 0.00 | 0.00 | 4.21M | 10.11M | 8.04M | 38.62M | 32.63M | 72.44M | 7.12M | 8.07M | 15.46M | 15.19M | 20.11M | 34.30M | 27.27M | 23.34M | 26.89M | 18.37M | 21.36M | 26.90M | 24.71M | 15.46M | 7.49M | 3.73M | 2.10M | 900.00K | 400.00K |
| General & Administrative | 65.34M | 43.39M | 54.76M | 103.92M | 108.07M | 118.42M | 192.00M | 200.40M | 197.05M | 119.33M | 105.18M | 97.65M | 54.21M | 17.51M | 16.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 4.40M | 3.40M | 1.80M | 400.00K | 800.00K | 800.00K | 3.70M | 4.10M | 2.30M | 1.80M | 2.40M | 1.50M | 27.34M | 31.42M | 23.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 78.64M | 46.79M | 56.56M | 104.32M | 108.87M | 119.22M | 195.70M | 204.50M | 199.35M | 121.13M | 105.18M | 97.65M | 81.54M | 48.93M | 40.25M | 26.40M | 26.69M | 22.67M | 11.64M | 5.18M | 3.48M | 5.37M | 2.53M | 2.03M | 1.87M | 2.00M | 1.00M | 400.00K |
| Other Expenses | 287.10M | 32.61M | 28.11M | 24.78M | 101.77M | 101.77M | 102.75M | 106.85M | 599.00K | 10.16M | -249.00K | 481.00K | 0.00 | 0.00 | 0.00 | -7.50M | -34.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 561.76K | 643.49K | 500.00K | 200.00K | 0.00 |
| Operating Expenses | 368.59M | 79.39M | 84.67M | 133.32M | 220.75M | 229.03M | 337.06M | 343.97M | 355.14M | 138.40M | 117.80M | 115.13M | 96.73M | 69.04M | 74.54M | 46.17M | 15.45M | 49.56M | 30.01M | 26.54M | 30.38M | 30.09M | 17.99M | 10.08M | 6.25M | 4.60M | 2.10M | 800.00K |
| Cost & Expenses | 395.61M | 98.14M | 100.50M | 153.19M | 230.25M | 247.51M | 409.66M | 431.39M | 423.04M | 153.55M | 124.89M | 121.17M | 102.28M | 77.14M | 79.80M | 51.94M | 18.04M | 51.16M | 30.92M | 26.54M | 30.38M | 30.09M | 17.99M | 9.51M | 5.61M | 4.10M | 1.90M | 800.00K |
| Interest Income | 0.00 | 7.96M | 10.22M | 15.93M | 58.39M | 1.20M | 681.00K | 485.00K | 599.00K | 215.00K | 662.00K | 520.00K | 557.00K | 839.00K | 1.05M | 2.35M | 2.27M | 2.03M | 1.45M | 489.01K | 299.14K | 101.11K | 0.00 | 222.95K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.38M | 7.96M | 10.22M | 15.93M | 58.39M | 68.88M | 73.55M | 83.72M | 73.44M | 23.92M | 4.49M | 39.00K | 133.00K | 572.00K | 1.00M | 555.00K | 0.00 | 0.00 | 459.74K | 928.88K | 910.42K | 732.57K | 105.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 28.23M | 33.41M | 29.11M | 26.38M | 102.97M | 106.43M | 105.50M | 109.38M | 83.34M | 10.16M | 4.55M | 2.02M | 420.00K | 439.00K | 808.00K | 1.15M | 865.00K | 1.38M | 1.14M | 1.70M | 1.04M | 745.14K | 610.81K | 561.76K | 643.49K | 500.00K | 200.00K | 0.00 |
| EBITDA | -222.45M | 72.54M | 38.78M | -3.20M | -61.12M | 213.16M | 74.05M | 133.76M | 35.94M | 252.64M | 16.68M | -27.27M | 71.68M | 4.90M | -20.21M | -13.60M | 48.40M | -40.23M | -25.37M | -24.63M | -28.35M | -27.68M | -13.71M | -7.18M | -4.85M | -2.84M | -1.00M | -500.00K |
| EBITDA Ratio | -146.28% | 58.38% | 35.88% | -23.86% | 45.74% | 53.64% | 19.57% | 28.92% | 1.06% | 63.32% | 10.15% | -31.20% | -7.00% | 5.53% | -36.42% | -67.30% | 21.07% | -421.17% | -599.99% | -12,160.55% | -2,887.38% | -2,749.98% | -373.25% | -280.87% | 6,215.39% | -412.50% | -183.33% | -166.67% |
| Operating Income | -243.54M | 57.81M | 9.42M | -46.92M | 3.20M | 43.66M | -42.18M | 24.51M | -50.40M | 236.81M | 9.32M | -30.35M | 70.70M | 3.63M | -22.07M | -17.10M | 47.54M | -41.61M | -26.51M | -26.33M | -29.40M | -28.43M | -14.32M | -7.74M | -5.49M | -3.30M | -1.30M | -500.00K |
| Operating Income Ratio | -160.15% | 37.00% | 8.49% | -44.15% | 1.39% | 14.00% | -11.08% | 5.38% | -14.71% | 60.67% | 6.94% | -33.42% | 53.17% | 4.49% | -38.23% | -49.06% | 72.49% | -435.62% | -601.81% | -13,000.40% | -2,993.76% | -1,711.27% | -389.88% | -435.66% | -4,760.78% | -412.50% | -216.67% | -166.67% |
| Total Other Income/Expenses | -10.52M | -26.65M | -9.98M | 36.64M | -28.06M | -5.68M | -61.75M | -89.01M | -72.84M | -23.71M | -4.74M | 481.00K | 424.00K | 267.00K | 49.00K | 1.79M | 39.56M | 2.03M | 2.04M | -439.87K | -5.36K | 15.56M | -3.17M | -2.19M | -12.02M | 536.86K | 0.00 | 500.00K |
| Income Before Tax | -254.05M | 31.17M | -553.00K | -45.51M | -222.48M | 37.98M | -103.92M | -64.50M | -123.24M | 213.11M | 4.58M | -29.87M | 71.12M | 3.89M | -22.02M | -15.30M | 49.81M | -39.58M | -24.47M | -26.77M | -29.40M | -12.86M | -17.49M | -9.93M | -17.51M | -2.80M | 0.00 | 0.00 |
| Income Before Tax Ratio | -167.06% | 19.95% | -0.50% | -42.83% | -96.94% | 12.18% | -27.30% | -14.15% | -35.96% | 54.59% | 3.41% | -32.89% | 53.49% | 4.82% | -38.15% | -43.92% | 75.95% | -414.36% | -555.40% | -13,217.54% | -2,994.31% | -774.33% | -476.27% | -558.82% | -15,178.98% | -350.00% | 0.00% | 0.00% |
| Income Tax Expense | 77.89M | -78.46M | 728.00K | -17.37M | -5.28M | 1.07M | -1.43M | 24.22M | -47.50M | 81.35M | -38.73M | -91.00K | 396.00K | -4.00K | -15.00K | 1.00K | 592.00K | 82.50K | -2.04M | 99.00K | 611.28K | -17.37M | 105.20K | 1.96M | 11.72M | -500.00K | -100.00K | 500.00K |
| Net Income | -331.94M | 109.63M | -1.28M | -28.14M | -217.20M | 36.91M | -102.50M | -88.72M | -75.74M | 131.76M | 43.31M | -29.78M | 70.73M | 3.90M | -22.01M | -15.30M | 49.22M | -39.66M | -24.47M | -26.87M | -30.02M | -13.49M | -17.60M | -9.70M | -17.21M | -2.80M | -1.20M | -500.00K |
| Net Income Ratio | -218.28% | 70.17% | -1.15% | -26.48% | -94.64% | 11.84% | -26.92% | -19.46% | -22.10% | 33.75% | 32.27% | -32.79% | 53.19% | 4.82% | -38.12% | -43.92% | 75.05% | -415.23% | -555.40% | -13,266.41% | -3,056.56% | -812.35% | -479.13% | -546.27% | -14,921.74% | -350.00% | -200.00% | -166.67% |
| EPS | -4.67 | 2.33 | -0.03 | -1.07 | -12.29 | 2.31 | -6.54 | -5.80 | -5.04 | 9.04 | 3.04 | -2.13 | 5.20 | 0.28 | -1.71 | -1.25 | 4.24 | -3.82 | -2.46 | -3.10 | -4.91 | -3.69 | -6.89 | -5.29 | -10.63 | -1.77 | -1.08 | -0.48 |
| EPS Diluted | -4.67 | 2.01 | -0.03 | -1.07 | -12.29 | 2.30 | -6.54 | -5.79 | -5.04 | 8.20 | 3.00 | -2.13 | 5.04 | 0.28 | -1.71 | -1.25 | 4.20 | -3.82 | -2.46 | -3.10 | -4.91 | -3.69 | -6.89 | -5.29 | -10.63 | -1.77 | -1.08 | -0.48 |
| Weighted Avg Shares Out | 71.03M | 47.00M | 43.17M | 26.21M | 17.68M | 15.95M | 15.68M | 15.30M | 15.03M | 14.57M | 14.18M | 13.97M | 13.64M | 13.13M | 12.88M | 12.19M | 11.49M | 10.38M | 9.96M | 8.66M | 6.11M | 3.66M | 2.56M | 1.83M | 1.62M | 1.58M | 1.11M | 1.04M |
| Weighted Avg Shares Out (Dil) | 71.03M | 54.67M | 43.17M | 26.21M | 17.68M | 16.05M | 15.68M | 15.32M | 15.03M | 16.58M | 14.39M | 13.97M | 14.02M | 13.34M | 12.88M | 12.19M | 11.59M | 10.38M | 9.96M | 8.66M | 6.11M | 3.66M | 2.56M | 1.83M | 1.62M | 1.58M | 1.11M | 1.04M |
Assertio Holdings, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ASRT
NEW YORK, NY / ACCESSWIRE / February 25, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Assertio Holdings, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ASRT
NEW YORK, NY / ACCESSWIRE / February 25, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Investors in Assertio Holdings, Inc. Should Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT
NEW YORK, NY / ACCESSWIRE / February 24, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc.(ASRT) Shareholders
NEW YORK, NY / ACCESSWIRE / February 24, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Assertio Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - ASRT
NEW YORK , Feb. 24, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT). The class action, filed in the United States District Court for...
Class Action Filed Against Assertio Holdings, Inc. (ASRT) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / February 23, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Shareholders that lost money on Assertio Holdings, Inc.(ASRT) should contact Levi & Korsinsky about pending Class Action - ASRT
NEW YORK, NY / ACCESSWIRE / February 23, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
ASRT Investors Have Opportunity to Lead Assertio Holdings, Inc. Securities Fraud Lawsuit
LOS ANGELES , Feb. 23, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT).
Investors in Assertio Holdings, Inc. Should Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT
NEW YORK , Feb. 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf...
ASRT LAWSUIT ALERT: Levi & Korsinsky Notifies Assertio Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / February 23, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Source: https://incomestatements.info
Category: Stock Reports